Do rural health disparities affect prevalence data in pediatric eosinophilic esophagitis?

CEGIR Investigator Group

doi:10.1016/j.jaip.2021.03.027

Do rural health disparities affect prevalence data in pediatric eosinophilic esophagitis?

CEGIR Investigator Group

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	2549-2551
Number of pages	3
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	9
Issue number	6
DOIs	https://doi.org/10.1016/j.jaip.2021.03.027
State	Published - Jun 2021

Access to Document

10.1016/j.jaip.2021.03.027

Cite this

@article{c7bb978d0c97486b97f472aa5090bb1b,

title = "Do rural health disparities affect prevalence data in pediatric eosinophilic esophagitis?",

author = "{CEGIR Investigator Group} and Cameron Sabet and Klion, {Amy D.} and Dominique Bailey and Elizabeth Jensen and Mirna Chehade and Abonia, {J. Pablo} and Rothenberg, {Marc E.} and Furuta, {Glenn T.} and Muir, {Amanda B.}",

note = "Funding Information: Conflicts of interest: M. E. Rothenberg is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celgene, AstraZeneca, Arena Pharmaceuticals, Ellodi Pharma, GlaxoSmithKline, Regeneron/Sanofi, Guidepoint, and Suvretta Capital Management, and has an equity interest in the first five listed, and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust), and UpToDate; and is an inventor of patents owned by Cincinnati Children's Hospital. G. T. Furuta is the chief medical officer of EnteroTrack. M. Chehade is a consultant for Regeneron, Allakos, Adare, Shire/Takeda, AstraZeneca, Sanofi, and Bristol Myers Squibb and has research funding from Regeneron , Allakos , Shire , AstraZeneca , and Danone . The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Conflicts of interest: M. E. Rothenberg is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celgene, AstraZeneca, Arena Pharmaceuticals, Ellodi Pharma, GlaxoSmithKline, Regeneron/Sanofi, Guidepoint, and Suvretta Capital Management, and has an equity interest in the first five listed, and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust), and UpToDate; and is an inventor of patents owned by Cincinnati Children's Hospital. G. T. Furuta is the chief medical officer of EnteroTrack. M. Chehade is a consultant for Regeneron, Allakos, Adare, Shire/Takeda, AstraZeneca, Sanofi, and Bristol Myers Squibb and has research funding from Regeneron, Allakos, Shire, AstraZeneca, and Danone. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2021",

month = jun,

doi = "10.1016/j.jaip.2021.03.027",

language = "English",

volume = "9",

pages = "2549--2551",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",